Which therapeutic option for hepatitis C virus genotype 1?

Area of Science:

• Hepatology
• Virology
• Pharmacology

Background:

• Four direct-acting antiviral (DAA) regimens are available for chronic hepatitis C virus (HCV) genotype 1 infection: boceprevir, telaprevir, simeprevir, and sofosbuvir.
• Phase 3 studies for simeprevir and sofosbuvir did not include control arms, necessitating a comparison with earlier agents.

Purpose of the Study:

• To quantify the comparative effectiveness of simeprevir and sofosbuvir against boceprevir and telaprevir.
• To evaluate treatment outcomes based on patient and virological characteristics.

Main Methods:

• A literature review of phase 3 randomized placebo-controlled trials for the four DAAs.
• Comparison of sustained virological response (SVR) rates stratified by HCV genotype, viral load, IL28B polymorphism, and fibrosis stage.

Main Results:

• Simeprevir and sofosbuvir demonstrated superior SVR rates compared to boceprevir and telaprevir, with exceptions for telaprevir in treatment-naïve HCV genotype 1b patients.
• Sofosbuvir generally achieved higher SVR than simeprevir, except in treatment-naïve IL28B CC patients and treatment-naïve HCV genotype 1b patients.
• Simeprevir showed a moderate SVR improvement over telaprevir in treatment-naïve patients with F3-F4 fibrosis and HCV genotype 1a.

Conclusions:

• Sofosbuvir and simeprevir significantly enhance SVR rates compared to first-generation protease inhibitors.
• Treatment decisions can be guided by patient characteristics and financial considerations.
• These findings highlight the contribution of newer DAA regimens to achieving optimal SVR rates in HCV genotype 1 management.